Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 259

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 259
---
 than the close of business on February 13, 2025 nor later than the close of business on
March 15, 2025. In addition to satisfying the foregoing requirements under the Enfusion Bylaws, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other
than Enfusion’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act within the time period specified above. Stockholder proposals should be
addressed to: Enfusion, Inc., Attention: Legal Department, 125 South Clark Street, Suite 750, Chicago, IL 60603.

Enfusion Stockholders
are also advised to review the Enfusion Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. A copy of the full text of the bylaw provisions discussed above may be obtained from the
Governance subsection of the Investor Relations page of Enfusion’s website at http://ir.enfusion.com. The Enfusion Bylaws are also on file with the SEC and are available through its website at www.sec.gov.

185

HOUSEHOLDING OF PROXY STATEMENT/PROSPECTUS

The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and
annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement or annual report, as applicable, addressed to those stockholders. As permitted by the Exchange Act, only one copy of this Proxy
Statement/Prospectus is being delivered to stockholders residing at the same address, unless stockholders have notified Enfusion whose shares they hold of their desire to receive multiple copies of this Proxy Statement/Prospectus. This process,
which is commonly referred to as “householding,” potentially provides extra convenience for stockholders and cost savings for companies.

Two or more stockholders sharing an address can request delivery of a single copy of Enfusion’s annual disclosure documents and this
Proxy Statement/Prospectus if they are receiving multiple copies by calling Innisfree at (877) 750-0637 or writing to them at Innisfree M&A Incorporated, 501 Madison Avenue, 20 Floor, New York City, NY 10022. In the same way, two or more stockholders sharing an address and receiving only a single copy of Enfusion’s annual disclosure documents and this Proxy
Statement/Prospectus can request to each receive a